Galaxy™ has another in-built advantage. “We mimic the way the human immune system selects antibodies, by evolving the library itself during the short, efficient screening process. This unique feature of Galaxy™ allows us to improve antibodies present in the original library in a single pass, and makes Galaxy™ a more rapid route to a candidate in comparison to other competitor libraries” according to Finlay.
“Galaxy™ is the first technology to combine the principles of the in vivo antibody selection process, as used in humanized mice, with the flexibility of in vitro screening that allows functional screening for particular profiles”
Since Galaxy™ was completed, the RxBiologics team have successfully isolated numerous antibodies against well-known targets, to create an array of practical evidence for the superiority of the new library design. “Of course, I hoped the Galaxy™ design would out-perform existing approaches” said Finlay, who previously led Biologics Discovery in Europe for pharmaceutical giant Pfizer, “but I was delighted to see just how well it worked in practice. RxCelerate have been excellent partners, believing in the potential for Galaxy™ from the outset.”
Even prior to its official launch, RxBiologics have secured discovery projects from several existing RxCelerate clients. There are, however, a limited number of slots available for new clients while RxBiologics recruits further team members to expand capacity. “By the end of 2021 we expect to be able to conduct at least five screening campaigns in parallel” said Reckless.
“It is exciting to now have access to world-leading antibody discovery capability to complement our cutting-edge small molecule discovery services at RxCelerate” said David Grainger, Executive Chairman at RxCelerate. “Our vision is to democritise access to pharma-grade discovery and development, allowing anyone with a good idea to reduce it to practice. Galaxy™ fills an important gap in that capability.”